Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients. in Archives of gynecology and obstetrics / Arch Gynecol Obstet. 2024 Oct;310(4):2183-2190. doi: 10.1007/s00404-024-07670-4. Epub 2024 Aug 2.
2024
ASL Asti
ASL Asti
Tipo pubblicazione
Observational Study
Autori/Collaboratori (8)Vedi tutti...
Attianese D
Academic Division of Gynecology and Obstetrics, University of Torino, Mauriziano Umberto I Hospital, Torino, Italy.
Massobrio R
Academic Division of Gynecology and Obstetrics, University of Torino, Mauriziano Umberto I Hospital, Torino, Italy.
Giorgi M
Academic Division of Gynecology and Obstetrics, University of Torino, Mauriziano Umberto I Hospital, Torino, Italy.
et alii...
Academic Division of Gynecology and Obstetrics, University of Torino, Mauriziano Umberto I Hospital, Torino, Italy.
Massobrio R
Academic Division of Gynecology and Obstetrics, University of Torino, Mauriziano Umberto I Hospital, Torino, Italy.
Giorgi M
Academic Division of Gynecology and Obstetrics, University of Torino, Mauriziano Umberto I Hospital, Torino, Italy.
et alii...
Abstract
PURPOSE: Oral metronomic cyclophosphamide (OMC) implicates the daily administration of low doses of chemotherapy. Its antitumor activity combined with an oral administration route and a good toxicity profile makes OMC an attractive option for heavily pretreated patients. We retrospectively evaluated OMC's clinical benefit and objective response in recurrent ovarian cancer patients. METHODS: This is a retrospective observational study involving patients treated with OMC (50 mg daily) from 2017 to 2022 at the Academic Division Gynaecology, Mauriziano Hospital, Torino, Italy. Clinical benefit assessment included CA125 response, radiological response, and reported symptomatic improvement. Toxicities were reported using Common Terminology Criteria for Adverse Events version 5.0. RESULTS: Thirty-eight patients (average age 72, range 49-88) were included. 90% had FIGO stage III/IV at diagnosis and 64% underwent???3 previous lines of chemotherapy. Before OMC, 79% had ECOG 1 or 2. 8.6% of patients had a partial response (PR), and 40% a stable disease (SD). Median duration of response was 7.4 months. After 3 months on OMC, 51% experienced symptom improvement, and 53.3% experienced Ca125 reduction or stabilization. 66.7% of patients older than 75 responded to treatment; in 40% of cases, responses lasted???6 months (p?=?0.08).
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
Se sei accreditato in BVS-P effettua prima l'accesso per utilizzare i nostri servizi.
PMID : 39093333
DOI : 10.1007/s00404-024-07670-4
Keywords
Humans; Female; Cyclophosphamide/administration & dosage/adverse effects; Aged; Retrospective Studies; Middle Aged; Carcinoma, Ovarian Epithelial/drug therapy; Ovarian Neoplasms/drug therapy; Aged, 80 and over; Administration, Metronomic; Antineoplastic Agents, Alkylating/administration & dosage/adverse effects; Administration, Oral; Neoplasm Recurrence, Local/drug therapy; CA-125 Antigen/blood; Treatment Outcome; Clinical benefit; Elderly; Oral metronomic cyclophosphamide; Ovarian cancer;